NEW YORK (Reuters) - BiogenIdecInc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.

accumulate a lot of biotech names and participate in their big runs the past couple years. Names like Amgen AMGN and BiogenIdecBIIB contributed alongside a variety of other stocks like Southwest Airlines LUV, Micron Technology MU, and Charles

recognizes their worth, paid off in a big way in 2014. Notably, big biotech and pharmaceutical holdings--such as BiogenIdecBIIB , Amgen AMGN, Eli Lilly LLY, Roche, and Novartis NVS--in all six funds posted strong returns for the second